# Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab

> **NCT02248571** · PHASE4 · COMPLETED · sponsor: **iOMEDICO AG** · enrollment: 85 (actual)

## Conditions studied

- Breast Cancer Recurrent
- HER2/Neu-negative Carcinoma of Breast
- Hormone Receptor Positive Malignant Neoplasm of Breast

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Capecitabine
- **DRUG:** Everolimus
- **DRUG:** Exemestane
- **OTHER:** Patient questionaires

## Key facts

- **NCT ID:** NCT02248571
- **Lead sponsor:** iOMEDICO AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2017-08-31
- **Final completion:** 2017-09-30
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2017-11-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02248571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02248571, "Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02248571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*